Straumann with clear analyst view, shares trade steadily on SIX

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 09:56.

Straumann (CH0012280076) stands in front of investors on the SIX Swiss Exchange with a broadly positive analyst backdrop. Consensus data compiled by MarketScreener point to a majority of Buy recommendations and an average price target meaningfully above the current share price.

What analysts are saying

According to the aggregated overview on MarketScreener, around two thirds of the banks following Straumann currently rate the stock Buy or Outperform, while the remainder mostly sit at Hold ratings, reflecting a cautious but constructive stance on the medtech group MarketScreener consensus for Straumann. The compiled 12-month price targets cluster above the present level, indicating expected upside without signaling euphoria.

Swiss brokers such as UBS and Vontobel have in recent months underlined Straumann’s strong position in premium dental implants and clear aligners, but they also point to risks from pricing pressure and macro-sensitive demand for elective dental procedures recent Swiss equity research commentary. In their sector work, Straumann is frequently benchmarked against international peers like Dentsply Sirona and Align Technology, with the Swiss group described as structurally well positioned but not immune to cyclical swings.

Valuation and peer comparison

On standard valuation metrics such as the price-earnings ratio, Straumann typically trades at a premium to broader European medtech names, reflecting its higher structural growth profile, according to data collated by MarketWatch and other financial portals MarketWatch profile of Straumann. Analysts highlight that this valuation premium requires the company to deliver consistent mid- to high-single-digit organic growth and to maintain its margin profile.

Sector reports from international houses compare Straumann’s growth and profitability with peers in orthodontics and implants, noting that the group’s exposure to emerging markets like China and Latin America adds both opportunity and volatility Reuters medtech sector outlook. In these comparisons, Straumann is often cited as a key European pure play on dental consumables, differing from diversified medtech groups that combine several therapy areas.

How Straumann makes its money

Straumann generates the bulk of its revenue with dental implant systems, prosthetic components and regenerative products sold to dentists and dental clinics worldwide, complemented by clear-aligner solutions for orthodontic tooth correction. A representative product line is the Straumann BLT implant system, designed for immediate and early loading in various clinical situations.

Where the shares trade now

The Straumann shares (CH0012280076) trade on the SIX Swiss Exchange in Zurich; the latest available data on the exchange website show the stock quoted in Swiss francs during regular trading hours.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All information is based on sources deemed reliable but cannot be guaranteed. Investors should conduct their own research and, where appropriate, seek professional advice.